|
answer text |
<p>The Cancer Drugs Fund (CDF) has helped over 84,000 people in England to access
life-extending cancer drugs that would not otherwise have been available to them.</p><br
/><p>Prior to April 2013, the Fund was administered through clinical panels based
in each of the 10 strategic health authorities (SHAs). Cumulative information on the
number of different treatments financed by SHAs through the CDF for this period is
as follows:</p><br /><p>2011-12: approximately 89 treatments<sup>1</sup></p><p>2012-13:
approximately 114 treatments<sup>1</sup></p><p><sup></sup></p><p><sup>1</sup>Information
on the type of cancer being treated was not collected</p><p><em>Source:</em> Information
provided to the Department by SHAs as part of financial monitoring arrangements</p><br
/><p>Since April 2013, NHS England has had responsibility for the Fund and it publishes
information on CDF activity routinely on its website at:</p><br /><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/"
target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p><strong></strong></p><p>The
National Audit Office report, <em>Investigation into the Cancer Drugs Fund</em>, details
the number of treatments available through the national CDF list from April 2013 as
follows:</p><br /><p>April 2013: 24 treatments covering 53 indications</p><p>April
2014: 40 treatments covering 78 indications</p><p>April 2015: 39 treatments covering
67 indications</p><br /><p><em>Source:</em> National Audit Office report <em>Investigation
into the Cancer Drugs Fund</em><em>, </em>published 17 September 2015</p><p><em></em></p><p>Decisions
on which treatments are included on the national CDF list are made by the expert CDF
clinical panel because it is right these decisions are clinically led. NHS England
periodically reviews the national CDF list, adding new drugs or drugs indications
to the list and/or removing drug indications from the list, for example when the indications
have been recommended by the National Institute for Health and Care Excellence for
routine commissioning. Currently, 33 treatments covering 47 indications are listed.</p>
|
|